Indaptus Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $1 | $0 |
Gross Profit | ||||
EBITDA | -5,228 | -4,572 | -4,171 | -3,142 |
EBIT | -4,171 | |||
Net Income | -5,228 | -4,532 | -4,131 | -3,069 |
Net Change In Cash | 0 | 0 | 1 | 0 |
Free Cash Flow | -4,018 | -5,047 | -3,395 | -2,513 |
Cash | 6,157 | 3,891 | 5,786 | 7,380 |
Basic Shares | 574 | 9,355 | 9,355 | 9,510 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1 | -1 | -1 | |
EBITDA | -15,021 | -16,377 | -14,909 | -7,727 |
EBIT | -15,022 | -16,378 | -14,910 | -7,729 |
Net Income | -15,022 | -15,423 | -14,322 | -7,693 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -12,323 | -13,405 | -13,250 | -11,294 |
Cash | 5,786 | 13,362 | 9,626 | 39,132 |
Basic Shares | 9,355 | 8,401 | 8,262 | 4,090 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$9.09 |
2025-03-31 | -$9 |
2024-12-31 | -$0.37 |
2024-09-30 | -$0.32 |
